No Data
No Data
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $36
Piper Sandler Sticks to Its Hold Rating for Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript Summary
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
Strong Q3 Performance and Promising Future for Supernus Pharmaceuticals Backed by Qelbree's Success